Ísrael - hebreska - Ministry of Health

ניקנור (1987) בעמ - רחצת הגוף

Ísrael - hebreska - Ministry of Health

לילית קוסמטיקה בעמ - רחצת הגוף

Ísrael - hebreska - Ministry of Health

ביוקאר בעמ - רחצת הגוף

Ísrael - hebreska - Ministry of Health

taro pharmaceutical industries ltd - chlorhexidine gluconate - תמיסה - chlorhexidine gluconate 0.2 %w/v - chlorhexidine - chlorhexidine - 1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.

Ísrael - hebreska - Ministry of Health

j-c health care ltd - miconazole - ג'ל - miconazole 20 mg/g - miconazole - miconazole - oral mycosis (thrush) and fungal infections of the upper gastrointestinal tract. daktarin oral gel can be used for the prevention of oral thrush in patient receiving long-term treatment with antibiotics, steroids, cytotoxic and radiation therapy.

Ísrael - hebreska - Ministry of Health

rafa laboratories ltd - omeprazole - קפסולות - omeprazole 20 mg - omeprazole - omeprazole - relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.

Ísrael - hebreska - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 40 mg - pantoprazole - pantoprazole - short term treatment of acute duodenal ulcer. acute gastric ulcer. moderate and severe reflux esophagitis. eradication of helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing of duodenal and gastric ulcers caused by this microorganism. zollinger ellison syndrome.

Ísrael - hebreska - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 20 mg - pantoprazole - pantoprazole - treatment of reflux oesophagitis and associated symptoms (e.g. hearburn acid regurgitation pain on swallowing) . for long-term management and prevention of relapse in reflux oesophagitis. prevention of gastroduodenal ulcers induced by non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaids treatment.

Ísrael - hebreska - Ministry of Health

rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Ísrael - hebreska - Ministry of Health

rafa laboratories ltd - lansoprazole - קפסולות - lansoprazole 15 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long- term treatment and maintenance therapy for patients with gastro-oesophageal reflux disease (gerd) or duodenal ulcer. prevention of relapse in patients with gerd or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients ,with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short- term- treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.